A Phase III Study of Octreotide versus Placebo for Acromegaly Previously Treated with Hormonal Injections

Full Title

OOC-ACM-303:A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Previously Tolerated and Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment


In patients with acromegaly, the pituitary gland produces too much growth hormone. The standard treatment includes hormonal drugs such as injections of octreotide or lanreotide. In this study, researchers are comparing the effectiveness of octreotide capsules (taken by mouth) to a placebo (inactive drug) for treating patients with acromegaly who previously responded well to somatostatin injections.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have acromegaly as a result of a pituitary tumor that is overproducing growth hormone.
  • Patients must have responded to prior treatment with octreotide or lanreotide injections and received them for at least 6 months, with a stable dose for at least the last 3 months of therapy.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Eliza Geer at 646-888-2627.